Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT 1A receptors without diminishing nervous system function or chemotherapy efficacy

British Journal of Pharmacology

Volumn 171, Issue 3, 2014, Pages 636-645

  Ward, Sara Jane ^a   McAllister, Sean D ^b   Kawamura, Rumi ^b   Murase, Ryuchi ^b   Neelakantan, Harshini ^c   Walker, Ellen A ^c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

5 HT 1A; breast cancer; cannabidiol; cannabinoid; chemotherapy induced neuropathic pain; CIPN; mechanical sensitivity; paclitaxel

Indexed keywords

5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABIDIOL; CANNABINOID; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PACLITAXEL; RIMONABANT; SEROTONIN 1A RECEPTOR;

ALLODYNIA; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CELL VIABILITY; CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; IC 50; MOUSE; NERVOUS SYSTEM FUNCTION; NEUROPATHIC PAIN; NONHUMAN; OPERANT BEHAVIORAL TEST; PRIORITY JOURNAL;

5-HT1A; BREAST CANCER; CANNABIDIOL; CANNABINOID; CHEMOTHERAPY-INDUCED NEUROPATHIC PAIN; CIPN; MECHANICAL SENSITIVITY; PACLITAXEL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BEHAVIOR, ANIMAL; BRAIN; BREAST NEOPLASMS; CANNABIDIOL; CELL LINE, TUMOR; CELL SURVIVAL; CONDITIONING, OPERANT; DRUG SYNERGISM; FEMALE; HUMANS; MEMORY; MICE; MICE, INBRED C57BL; NEURALGIA; NEURONS; NEUROPROTECTIVE AGENTS; PACLITAXEL; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS;

EID: 84892409960     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12439     Document Type: Article

References (67)

1. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C, (2000). The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406: 25-32.
2. Alves FH, Crestani CC, Gomes FV, Guimarães FS, Correa FM, Resstel LB, (2010). Cannabidiol injected into the bed nucleus of the stria terminalis modulates baroreflex activity through 5-HT1A receptors. Pharmacol Res 62: 228-236.
3. Argyriou AA, Assimakopoulos K, Iconomou G, Giannakopoulou F, Kalofonos HP, (2011). Either called 'chemobrain' or 'chemofog,' the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manage 41: 126-139.
4. Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F, et al. (2012). Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 90: 925-934.
5. Baron R, Binder A, Wasner G, (2010). Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 9: 807-819.
6. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852.
7. Bitencourt RM, Pamplona FA, Takahashi RN, (2008). Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 18: 849-859.
8. Campos AC, Ortega Z, Palazuelos J, Fogaça MV, Aguiar DC, Díaz-Alonso J, (2013). The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol 16: 1407-1419.
9. Casarotto PC, Gomes FV, Resstel LB, Guimarães FS, (2010). Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav Pharmacol 21: 353-358.
10. Cavaletti G, Tredici G, Braga M, Tazzari S, (1995). Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 133: 64-72.
11. Chou TC, (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
12. Chou TC, Tan QH, Sirotnak FM, (1993). Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother Pharmacol 31: 259-264.
13. Collier RJ, Wang Y, Smith SS, Martin E, Ornberg R, Rhoades K, (2011a). Complement deposition and microglial activation in the outer retina in light-induced retinopathy: inhibition by a 5-HT1A agonist. Invest Ophthalmol Vis Sci 52: 8108-8116.
14. Collier RJ, Patel Y, Martin EA, Dembinska O, Hellberg M, Krueger DS, (2011b). Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress. Invest Ophthalmol Vis Sci 52: 2118-2126.
15. Colpaert FC, (2006). 5-HT(1A) receptor activation: new molecular and neuroadaptive mechanisms of pain relief. Curr Opin Investig Drugs 7: 40-47.
16. Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B, (2008). Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. Phytother Res 22: 1017-1024.
17. Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M, (2004). Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 143: 247-250.
18. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M, (2007). The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 556: 75-83.
19. Deng L, Guindon J, Vemuri VK, Thakur GA, White FA, Makriyannis A, et al. (2012). The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. Mol Pain 8: 71.
20. Dixon WJ, (1980). Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20: 441-462.
21. Do Monte FH, Souza RR, Bitencourt RM, Kroon JA, Takahashi RN, (2013). Infusion of cannabidiol into infralimbic cortex facilitates fear extinction via CB1 receptors. Behav Brain Res 250: 23-27.
22. El-Remessy AB, Tang Y, Zhu G, Matragoon S, Khalifa Y, Liu EK, et al. (2008). Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Mol Vis 14: 2190-2203.
23. Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee R, Mechoulam R, et al. (2013). Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 75: 323-333.
24. Finnerup NB, Sindrup SH, Jensen TS, (2010). The evidence for pharmacological treatment of neuropathic pain. Pain 150: 573-581.
25. Foley JJ, Raffa RB, Walker EA, (2008). Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory. Psychopharmacology (Berl) 199: 527-538.
26. Gauchan P, Andoh T, Ikeda K, Fujita M, Sasaki A, Kato A, et al. (2009). Mechanical allodynia induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and different expression of voltage-dependent calcium channel alpha(2)delta-1 subunit. Biol Pharm Bull 32: 732-734.
27. Guindon J, Hohmann AG, (2008). Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153: 319-334.
28. Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, et al. (2008). Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur Neuropsychopharmacol 8: 448-454.
29. Hu P, McLachlan EM, (2002). Macrophage and lymphocyte invasion of dorsal root ganglia after peripheral nerve lesions in the rat. Neuroscience 112: 23-38.
30. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R, (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
31. Jenkins DE, Hornig YS, Oei Y, Dusich J, Purchio T, (2005). Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 7: R444-R454.
32. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT, (2010). Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39: 167-179.
33. Karschner EL, Darwin WD, McMahon RP, Liu F, Wright S, Goodwin RS, et al. (2011). Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 89: 400-407.
34. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
35. Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, (2013). A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 260: 984-997.
36. Lichtman AH, Varvel SA, Martin BR, (2002). Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids 66: 269-285.
37. Lynch JJ 3rd, Wade CL, Zhong CM, Mikusa JP, Honore P, (2004). Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain 110: 56-63.
38. McAllister SD, Chan C, Taft RJ, Luu T, Abood ME, Moore DH, et al. (2005). Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. J Neurooncol 74: 31-40.
39. McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY, (2007). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 6: 2921-2927.
40. McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J, et al. (2011). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 129: 37-47.
41. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
42. Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, et al. (2011). Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol 162: 584-596.
43. Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J, et al. (2010). Cannabidiol enhances the inhibitory effects of delta9- tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 9: 180-189.
44. Massi P, Solinas M, Cinquina V, Parolaro D, (2013). Cannabidiol as potential anticancer drug. Br J Clin Pharmacol 75: 303-312.
45. Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanchian G, et al. (2011). Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med 50: 1368-1381.
46. Naguib M, Diaz P, Xu JJ, Astruc-Diaz F, Craig S, Vivas-Mejia P, et al. (2008). MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol 155: 1104-1116.
47. Parker LA, Burton P, Sorge RE, Yakiwchuk C, Mechoulam R, (2004). Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) 175: 360-366.
48. Pascual D, Goicoechea C, Suardíaz M, Martín MI, (2005). A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. Pain 118: 23-34.
49. Peters CM, Jimenez-Andrade JM, Jonas BM, Sevcik MA, Koewler NJ, Ghilardi JR, et al. (2007). Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp Neurol 203: 42-54.
50. Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W, (2006). Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain-a randomized controlled trial. Wien Klin Wochenschr 118: 327-335.
51. Rahn EJ, Makriyannis A, Hohmann AG, (2007). Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol 152: 765-777.
52. Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG, (2008). Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther 327: 584-591.
53. Russo EB, Burnett A, Hall B, Parker KK, (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037-1043.
54. Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J, (2007). Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 26: 843-851.
55. Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J, (2011). Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. J Neurosci Res 89: 1509-1518.
56. Skrabek RQ, Galimova L, Ethans K, Perry D, (2008). Nabilone for the treatment of pain in fibromyalgia. J Pain 9: 164-173.
57. Stern CA, Gazarini L, Takahashi RN, Guimarães FS, Bertoglio LJ, (2012). On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment. Neuropsychopharmacology 37: 2132-2142.
58. Toth CC, Jedrzejewski NM, Ellis CL, Frey WH 2nd, (2010). Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol Pain 6: 16.
59. Viisanen H, Pertovaara A, (2010). Roles of the rostroventromedial medulla and the spinal 5-HT(1A) receptor in descending antinociception induced by motor cortex stimulation in the neuropathic rat. Neurosci Lett 476: 133-137.
60. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C, (2007). Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 11: 901-913.
61. Wade DT, Makela P, Robson P, House H, Bateman C, (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10: 434-441.
62. Ward SJ, Ramirez MD, Neelakantan H, Walker EA, (2011). Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice. Anesth Analg 113: 947-950.
63. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. (2010). Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 182: E694-E701.
64. Xiao W, Boroujerdi A, Bennett GJ, Luo ZD, (2007). Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience 144: 714-720.
65. Xiao W, Naso L, Bennett GJ, (2008). Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med 9: 505-517.
66. Xiao WH, Bennett GJ, (2008). C-fiber spontaneous discharge evoked by chronic inflammation is suppressed by a long-term infusion of lidocaine yielding nanogram per milliliter plasma levels. Pain 137: 218-228.
67. Xiong W, Cui T, Cheng K, Yang F, Chen SR, Willenbring D, et al. (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. J Exp Med 209: 1121-1134.